Vahtera A, et al. – Researchers set up a randomized and crossover trial to analyze whether enoxaparin thromboprophylaxis given as a continuous intravenous infusion (CII) results in more constant and predictable anti–factor Xa (anti–FXa) concentration than standard subcutaneous bolus (SCB) administration. The results of this study displayed that continuous infusion of enoxaparin led to lower anti–FXa Cmax24 h than standard SCB administration. In addition, no difference in anti–FXa AUC0–24 h was detected.